๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nasopharyngeal Cancinoma (NPC)
Clinical trial register · China

Nasopharyngeal Cancinoma (NPC) Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 21 Fuzhou 5 Shenzhen 4 Nanning 3 Changsha 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou21 Fuzhou5 Shenzhen4 Nanning3 Changsha3
All 27 locations
Target enrolment
to

Nasopharyngeal Cancinoma (NPC) trials in China

33 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Platinum-Free Regimen in Nasopharyngeal Carcinoma
NCT07794488Nasopharyngeal Cancinoma (NPC)
Zhejiang Cancer Hospital
Phase 2
145
Hangzhou
2026-09-01
Recruiting
Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal Carcinoma
NCT07796789Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
204
Guangzhou, Changsha, Fuzhou
2026-08-30
Recruiting
Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
NCT07528183Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
62
Fuzhou, Guangzhou, Nanning, Wuhan
2026-07-22
Recruiting
Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma
NCT07705243Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
86
Guangzhou
2026-07-20
Recruiting
Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors
NCT07625423Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC)
West China Hospital
Phase 1
9
Chengdu
2026-03-27
Recruiting
Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma
NCT07362979Nasopharyngeal Cancinoma (NPC)
DrugCCRT
Sun Yat-sen University
Phase 2
243
Dongguan, Guangzhou, Shenzhen, Zhanjiang
2026-03-12
Recruiting
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
NCT07496190Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
59
Guangzhou
2026-02-10
Recruiting
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
NCT07325539Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2026-01-12
Recruiting
IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
NCT07376603Nasopharyngeal Cancinoma (NPC), Intensity-modulated Radiotherapy, Stage IB
Qiaojuan Guo
Observational
169
Fuzhou
2026-01-12
Recruiting
International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
NCT07013461Nasopharyngeal Cancinoma (NPC)
The University of Hong Kong-Shenzhen Hospital
Observational
5,000
Shenzhen
2026-01-09
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Active, closed
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
Adaptive Immunotherapy for Nasopharyngeal Carcinoma
NCT07154069Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
802
Guangzhou
2025-11-13
Active, closed
Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial
NCT07248696Nasopharyngeal Cancinoma (NPC)
Chongqing University Cancer Hospital
Not applicable
32
Chongqing
2025-10-04
Active, closed
Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC
NCT07248670Nasopharyngeal Cancinoma (NPC)
Chongqing University Cancer Hospital
Phase 3
252
Chongqing
2025-10-04
Not yet open
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07138989Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
10
Guangzhou
2025-08-19
Not yet open
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma
NCT07110558Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
59
Guangzhou
2025-08-15
Not yet open
Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity
NCT07072000Nasopharyngeal Cancinoma (NPC)
Hai-Qiang Mai,MD,PhD
Phase 3
550
Foshan, Guangzhou, Zhangjiang, Liuzhou, Wuzhou
2025-08-01
Recruiting
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
NCT06802835Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2
148
Guangzhou
2025-07-09
Recruiting
Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma
NCT06912698Nasopharyngeal Cancinoma (NPC)
Hai-Qiang Mai,MD,PhD
Phase 3
342
Guangzhou
2025-05-22
Recruiting
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
NCT06749899Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center
Phase 3
580
Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan
2025-05-04
Not yet open
GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma
NCT06605131Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2
72
Guangzhou
2025-04-17
Recruiting
Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC
NCT06846450Nasopharyngeal Cancinoma (NPC)
Lin Kong, MD
Phase 3
470
Shanghai
2025-04-01
Active, closed
Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.
NCT06854510Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 2/3
196
Guangzhou
2025-02-21
Recruiting
Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI
NCT06831357Nasopharyngeal Cancinoma (NPC), Distant Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2025-02-15
Recruiting
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
NCT06788002Nasopharyngeal Cancinoma (NPC)
Hunan Cancer Hospital
Phase 2
26
Changsha, Chenzhou, Huaihua, Shaoyang, Yueyang
2025-01-14
Active, closed
Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma
NCT06770699Nasopharyngeal Cancinoma (NPC)
Jiangxi Provincial Cancer Hospital
Observational
260
Nanchang
2025-01-01
Recruiting
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06669611Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
242
Guangzhou
2024-11-27
Recruiting
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
NCT06829147Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2024-11-19
Recruiting
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
NCT06676722Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
DrugSBRT
The First Affiliated Hospital of Xiamen University
Phase 2
20
Xiamen
2024-11-05
Active, closed
TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06664983Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
84
Guangzhou
2024-10-21
Recruiting
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
NCT07067268Nasopharyngeal Cancinoma (NPC)
Fudan University
Phase 2
76
Shanghai
2024-09-14
Active, closed
Selective Neck Dissection Under Multimodal Assessment for N3 Nasopharyngeal Carcinoma After Radiotherapy
NCT07636499Nasopharyngeal Cancinoma (NPC)
Guiquan Zhu
Phase 1
50
Chengdu
2022-08-30
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/nasopharyngeal-cancinoma-npc

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies listing the condition Nasopharyngeal Cancinoma (NPC).

How many Nasopharyngeal Cancinoma (NPC) trials are recruiting in China?

21 of the 33 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nasopharyngeal Cancinoma (NPC)), 33 studies
PhaseStudiesRecruitingShare
Phase 312836.4%
Phase 211733.3%
Observational5415.2%
Phase 1216.1%
Not applicable103%
Phase 1/2113%
Phase 2/3103%

Most active sponsors

Lead sponsors with the most studies (Nasopharyngeal Cancinoma (NPC))
Lead sponsorStudiesRecruiting
Sun Yat-sen University1812
Chongqing University Cancer Hospital20
Hai-Qiang Mai,MD,PhD21
Fudan University11
Guiquan Zhu10
Hunan Cancer Hospital11
Jiangxi Provincial Cancer Hospital10
Lin Kong, MD11
Qiaojuan Guo11
Sun Yat-Sen University Cancer Center11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.